Expression of DNA mismatch repair proteins MLH1, MSH2, and MSH6 in recurrent glioblastoma

Neurological Research

Volumn 37, Issue 2, 2015, Pages 95-105

  Stark, Andreas M ^a   Doukas, Alexander ^a   Hugo, Heinz Herrmann ^a   Hedderich, Jürgen ^a   Hattermann, Kirsten ^b   Mehdorn, H Maximilian ^a   Held Feindt, Janka ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

Gene targeting; Glioblastoma; Mismatch repair

Indexed keywords

ARTICLE; COMPUTER GRAPHICS; COMPUTER SIMULATION; HUMAN; NEUROSURGERY; PROPRIOCEPTION; SCANNING ELECTRON MICROSCOPY; TACTILE DISCRIMINATION; TRAINING; VIRTUAL REALITY; VISUAL FIELD; ADULT; AGED; BIOSYNTHESIS; DNA METHYLATION; FEMALE; GENETICS; GLIOBLASTOMA; MALE; METABOLISM; MIDDLE AGED; MISMATCH REPAIR; MORTALITY; PROMOTER REGION; SURVIVAL; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

DNA BINDING PROTEIN; DNA LIGASE; DNA METHYLTRANSFERASE; G-T MISMATCH-BINDING PROTEIN; MGMT PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AGED, 80 AND OVER; DNA METHYLATION; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NEOPLASM RECURRENCE, LOCAL; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84919340263     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132814Y.0000000409     Document Type: Article

References (25)

1. Kleihues P, Burger PC, Aldape KD, Brat DJ, Biernat W, Bigner DD et al. Glioblastoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Lyon: IARC Press; 2007. p. 33-52.
2. Filippini G, Falcone C, Boiardi A, Broggi G, Bruzzone MG, Caldiroli D, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol. 2008;10:79-87.
3. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95:190-8.
4. Lun M, Lok E, Gautam S, Wu E, Wong ET. The natural history of extracranial metastasis from glioblastoma multiforme. J Neurooncol. 2011;105:261-73.
5. Stark AM, van de Bergh J, Hedderich J, Mehdorn HM, Nabavi A. Glioblastoma: clinical characteristics, prognostic factors and survival in 492 patients. Clin Neurol Neurosurg. 2012;114:840-5.
6. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncology. 1999;1:44-51.
7. Scherer HJ. Cerebral astrocytomas and their derivatives. Am J Cancer. 1940;40:159-98.
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96.
9. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
10. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA, Reavie LB, et al. Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. Clin Cancer Res. 2007;13:2038-45.
11. Felsberg J, Thon N, Eigenbrod S, Hentschel B, Sabel MC, Westphal M, et al. German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011;129:659-70.
12. Kunkel TA, Erie DA. DNA mismatch repair. Annu Rev Biochem. 2005;74:681-710.
13. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res. 2010;16:5107-13.
14. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat Res. 2001;486:71-87.
15. Kolodner RD, Marsischky GT. Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999;9:89-96.
16. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS, Rasheed A, et al. Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. Clin Cancer Res. 2008;14:4859-68.
17. Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat. 1997;10:89-99.
18. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res. 2006;66:3987-91.
19. Stark AM, Doukas A, Hugo HH, Mehdorn HM. The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res. 2010;32:816-20.
20. Stark AM, Witzel P, Strege RJ, Hugo HH, Mehdorn HM. p53, mdm2, EGFR and msh2 expression in paired initial and recurrent glioblastoma multiforme. J Neurol Neurosurg Psychiatry. 2003;74:779-83.
21. Hattermann K, Mehdorn HM, Mentlein R, Schultka S, Held-Feindt J. A methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. Anal Biochem. 2008;377:62-71.
22. Velasco A, Hewitt SM, Albert PS, Hossein M, Rosenberg H, Martinez C, et al. Differential expression of the mismatch repair gene hMSH2 in malignant prostate tissue is associated with cancer recurrence. Cancer. 2002;1:690-9.
23. Mu D, Tursun M, Duckett DR, Drummond JT, Modrich P, Sancar A. Recognition and repair of compound DNA lesions (base damage and mismatch) by human mismatch repair and excision repair systems. Mol Cell Biol. 1997;17:760-9.
24. Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol. 1998;16:3851-7.
25. Rellecke P, Kuchelmeister K, Schachenmayr W, Schlegel J. Mismatch repair protein hMSH2 in primary drug resistance in in vitro human malignant gliomas. J Neurosurg. 2004;101:653-8.